Masaru Matsuda sold $314k of ARQT
See Remarks at Arcutis Biotherapeutics, Inc.. 12,058 shares at an average of $26.03, traded Feb 27, 2026, filed Mar 3, 2026.
Score components
- +15RoleOfficer
- +14Trade size$314k at market
- 0Share of holdings soldSold 8.2% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-014326, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | AGrant or award Common Stock10b5-1 | +37,000 | $0.00 | $0 | 147,003 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -3,325 | $27.95 | $93k | 143,678 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -6,553 | $25.16 | $165k | 137,125 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -193 | $25.91 | $5,001 | 136,932 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -1,987 | $25.70 | $51k | 136,932 | Mar 3, 2026 |
| Feb 27, 2026 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +97,000 | $0.00 | $0 | 97,000 | Mar 3, 2026 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 28Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $257k 10,000 shares | -17% | |
| 40Moderate | Arcutis Biotherapeutics, Inc. | Keith R Leonard director | $997k 39,272 shares | -64% | |
| 21Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $158k 6,287 shares | -5% | |
| 25Weak | Arcutis Biotherapeutics, Inc. | Latha Vairavan SVP Chief Financial Officer | $72k 2,853 shares | -3% | |
| 34Weak | Arcutis Biotherapeutics, Inc. | Todd Watanabe See Remarks | $941k 37,349 shares | -5% | |
| 20Weak | Arcutis Biotherapeutics, Inc. | Larry Todd Edwards See Remarks | $93k 3,687 shares | -2% | |
| 17Weak | Arcutis Biotherapeutics, Inc. | Larry Todd Edwards See Remarks | $52k 2,052 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.